WO2001097792A3 - Neuraminidase inhibitors in the treatment of equine influenza virus infection - Google Patents

Neuraminidase inhibitors in the treatment of equine influenza virus infection Download PDF

Info

Publication number
WO2001097792A3
WO2001097792A3 PCT/IB2001/001402 IB0101402W WO0197792A3 WO 2001097792 A3 WO2001097792 A3 WO 2001097792A3 IB 0101402 W IB0101402 W IB 0101402W WO 0197792 A3 WO0197792 A3 WO 0197792A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
influenza virus
virus infection
equine influenza
neuraminidase inhibitors
Prior art date
Application number
PCT/IB2001/001402
Other languages
French (fr)
Other versions
WO2001097792A2 (en
Inventor
Masatoshi Fujiwara
Miyuki Itou
Tomoyuki Yokota
Original Assignee
Glaxosmithkline K K
Masatoshi Fujiwara
Ito Miyuki
Tomoyuki Yokota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline K K, Masatoshi Fujiwara, Ito Miyuki, Tomoyuki Yokota filed Critical Glaxosmithkline K K
Priority to AU2001272718A priority Critical patent/AU2001272718A1/en
Publication of WO2001097792A2 publication Critical patent/WO2001097792A2/en
Publication of WO2001097792A3 publication Critical patent/WO2001097792A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

This invention relates to a new veterinary use for compounds having neuraminidase inhibitor activity, such as oseltamivir and RWJ-270201 an derivative threat, and to medicaments containing them.
PCT/IB2001/001402 2000-06-22 2001-06-22 Neuraminidase inhibitors in the treatment of equine influenza virus infection WO2001097792A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001272718A AU2001272718A1 (en) 2000-06-22 2001-06-22 Medicaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015324.7 2000-06-22
GBGB0015324.7A GB0015324D0 (en) 2000-06-22 2000-06-22 Medicaments

Publications (2)

Publication Number Publication Date
WO2001097792A2 WO2001097792A2 (en) 2001-12-27
WO2001097792A3 true WO2001097792A3 (en) 2002-05-16

Family

ID=9894198

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2001/001402 WO2001097792A2 (en) 2000-06-22 2001-06-22 Neuraminidase inhibitors in the treatment of equine influenza virus infection
PCT/AU2001/000748 WO2001097804A1 (en) 2000-06-22 2001-06-22 Medicaments

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/AU2001/000748 WO2001097804A1 (en) 2000-06-22 2001-06-22 Medicaments

Country Status (3)

Country Link
AU (2) AU2001267135A1 (en)
GB (1) GB0015324D0 (en)
WO (2) WO2001097792A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913892B2 (en) 2005-04-21 2018-03-13 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US20070203241A1 (en) * 2006-02-13 2007-08-30 Babu Yarlagadda S Antiviral treatments
KR102323339B1 (en) * 2006-02-13 2021-11-08 바이오크리스트 파마수티컬즈, 인코퍼레이티드 Intravenous antiviral treatments
MX2008013140A (en) * 2006-04-12 2009-02-12 Biocryst Pharm Inc Intramuscular antiviral treatments.
CN102584637B (en) * 2011-01-17 2014-07-09 天津药物研究院 Peramivir hydrate crystal, preparation method, medical compound and usage thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026933A1 (en) * 1995-02-27 1996-09-06 Gilead Sciences, Inc. Novel selective inhibitors of viral or bacterial neuraminidases
WO1999033781A1 (en) * 1997-12-17 1999-07-08 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP249A (en) * 1990-04-24 1993-03-17 Biota Scient Management Pty Ltd Anti-viral compounds.
US5714509A (en) * 1995-05-03 1998-02-03 The University Of Alabama Inhibitors of bacterial sialidase and methods of making and using the same
PL333364A1 (en) * 1996-11-14 1999-12-06 Biota Scient Management Novel compounds and method of using them
WO2001029021A1 (en) * 1999-10-19 2001-04-26 Abbott Laboratories Neuraminidase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026933A1 (en) * 1995-02-27 1996-09-06 Gilead Sciences, Inc. Novel selective inhibitors of viral or bacterial neuraminidases
WO1999033781A1 (en) * 1997-12-17 1999-07-08 Biocryst Pharmaceuticals, Inc. Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DALE B. ET AL: "Nucleotide and deduced amino acid sequence of the influenza neuraminidase genes of the two equine serotypes.", VIROLOGY, vol. 155, no. 2, 1986, pages 460 - 468, XP001041751 *
GUBAREVA L V ET AL: "Influenza virus neuraminidase inhibitors", LANCET, vol. 355, no. 9206, 4 March 2000 (2000-03-04), pages 827 - 835, XP004263173, ISSN: 0140-6736 *
ROGERS G.N.; PAULSON J.C.: "Receptor determinants of human and animal influenza virus isolates differences in recptor specificity of the H-3 HEM agglutinin based on species of origin.", VIROLOGY, vol. 127, no. 2, 1983, pages 361 - 373, XP001041726 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9913892B2 (en) 2005-04-21 2018-03-13 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines

Also Published As

Publication number Publication date
AU2001267135A1 (en) 2002-01-02
AU2001272718A1 (en) 2002-01-02
GB0015324D0 (en) 2000-08-16
WO2001097804A1 (en) 2001-12-27
WO2001097792A2 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
NZ515392A (en) Respiratory syncytial virus replication inhibitors
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
WO2004037789A3 (en) Methylene urea derivatives as raf-kinase inhibitors
BRPI0409227A (en) compound, pharmaceutical composition, use of a compound, intermediate, and process for the preparation of a compound
TW200510375A (en) New compounds
WO2002008198A3 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
BR0306931A (en) Peptides as Hepatitis C Virus Serine-ns3 Protease Inhibitors
GEP20063938B (en) Hepatitis c virus inhibitors
UY28330A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A HISTONE DEACETILASE INHIBITOR
BR0308081A (en) Histone Deacetylase Inhibitors
BR9711095A (en) Substituted cyclopentane compound, composition and method for inhibiting influenza virus neuraminidase and method for treating influenza virus infection
NZ526913A (en) Inhibitors of cruzipain and other cysteine proteases
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2004094386A8 (en) Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
BRPI0410727A (en) compound, pharmaceutical composition, and use of a compound
DK1311256T3 (en) Use of derivatives of valproic acid amides and 2-valproic acid amides for the treatment or prevention of pain and / or headache disorders
WO2004085682A3 (en) Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza
WO2002028829A3 (en) Peptide deformylase inhibitors
BR0208688A (en) Lipid Decreasing Biphenyl Carboxamides
WO2001097792A3 (en) Neuraminidase inhibitors in the treatment of equine influenza virus infection
WO2006096769A3 (en) Use of alpha-glucosidase inhibitors to treat alphavirus infections
ATE253359T1 (en) ANTITHRBOTIC AGENTS
HUP0101224A2 (en) Pyrrolidine derivatives as inhibitors of neuraminidases and pharmaceutical compositions containing them
AU3719100A (en) Inhibitors of serine protease activity, methods and compositions for treatment of viral infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP